Literature DB >> 10048733

Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease.

A G Røseth1, P N Schmidt, M K Fagerhol.   

Abstract

BACKGROUND: Several studies have suggested that clinical indices of disease activity in inflammatory bowel disease (IBD) do not adequately reflect the degree of inflammation in most such patients. Faecal excretion of indium-111-labelled neutrophilic granulocytes has been suggested as the gold standard of disease activity, but its complexity and high cost and the exposure of patients to ionizing irradiation have limited the use of this technique. The aim of this study was to investigate the correlation between the faecal excretion of the granulocyte marker protein calprotectin and that of 111In-labelled granulocytes.
METHODS: Calprotectin in stool extracts from 19 patients with Crohn's disease (CD), 10 with ulcerative colitis (UC), and 9 presumably healthy controls was assessed with a simple enzyme-linked immunosorbent assay. Simultaneously, the faecal excretion of autologous 111In-labelled granulocytes was measured.
RESULTS: There was a strong correlation between the average daily excretion of calprotectin and that of the total 3-day excretion of 111In-labelled granulocytes (r = 0.87, P < 0.0001). Furthermore, the concentration of calprotectin, assessed in a small stool sample on day 1, also correlated well with the excretion 111In-labelled granulocytes (r = 0.80, P < 0.0001).
CONCLUSION: The results suggest that faecal calprotectin reflects the granulocyte migration through the gut wall in patients with IBD and hence might serve as a simple, inexpensive alternative to the indium-111 technique.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10048733     DOI: 10.1080/00365529950172835

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  99 in total

1.  Effect of Pentavac and measles-mumps-rubella (MMR) vaccination on the intestine.

Authors:  B Thjodleifsson; K Davídsdóttir; U Agnarsson; G Sigthórsson; M Kjeld; I Bjarnason
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

Review 2.  Evaluation of inflammatory activity in Crohn's disease and ulcerative colitis.

Authors:  Eduardo Garcia Vilela; Henrique Osvaldo da Gama Torres; Fabiana Paiva Martins; Maria de Lourdes de Abreu Ferrari; Marcella Menezes Andrade; Aloísio Sales da Cunha
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

3.  Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis.

Authors:  Hiroyuki Hanai; Fumitoshi Watanabe; Abby R Saniabadi; Isao Matsushitai; Ken Takeuchi; Takayuki Iida
Journal:  Dig Dis Sci       Date:  2002-10       Impact factor: 3.199

4.  Blue mode does not offer any benefit over white light when calculating Lewis score in small-bowel capsule endoscopy.

Authors:  Anastasios Koulaouzidis; Sarah Douglas; John N Plevris
Journal:  World J Gastrointest Endosc       Date:  2012-02-16

5.  Correlation of two capsule endoscopy scoring systems with fecal calprotectin: does it really matter?

Authors:  Suryakanth R Gurudu; Jonathan A Leighton
Journal:  Dig Dis Sci       Date:  2012-04       Impact factor: 3.199

Review 6.  Diagnostic accuracy of fecal lactoferrin for inflammatory bowel disease: a meta-analysis.

Authors:  Yan Wang; Fengyan Pei; Xingjuan Wang; Zhiyu Sun; Chengjin Hu; Hengli Dou
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

7.  Evaluation of Crohn's disease activity: initial validation of a magnetic resonance enterography global score (MEGS) against faecal calprotectin.

Authors:  Jesica C Makanyanga; Doug Pendsé; Nikolaos Dikaios; Stuart Bloom; Sara McCartney; Emma Helbren; Elaine Atkins; Terry Cuthbertson; Shonit Punwani; Alastair Forbes; Steve Halligan; Stuart A Taylor
Journal:  Eur Radiol       Date:  2013-09-12       Impact factor: 5.315

8.  Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis.

Authors:  Hiroyuki Hanai; Ken Takeuchi; Takayuki Iida; Nobuhito Kashiwagi; Abby R Saniabadi; Isao Matsushita; Yoshihiko Sato; Naoki Kasuga; Toshihiro Nakamura
Journal:  Dig Dis Sci       Date:  2004-09       Impact factor: 3.199

9.  Calprotectin as a diagnostic tool for inflammatory bowel diseases.

Authors:  Marianthi Chatzikonstantinou; Panagiotis Konstantopoulos; Spyros Stergiopoulos; Konstantinos Kontzoglou; Christos Verikokos; Despina Perrea; Dimitris Dimitroulis
Journal:  Biomed Rep       Date:  2016-09-07

10.  Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease.

Authors:  Michael Wagner; Christer G B Peterson; Peter Ridefelt; Per Sangfelt; Marie Carlson
Journal:  World J Gastroenterol       Date:  2008-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.